Conference Roundup

Bilateral simultaneous intravitreal injections appear safe, may reduce health care burden

Posted on

Bilateral intravitreal injections on the same day are safe, well-tolerated, and may help reduce health care burden, according to a poster presented at ASRS 2022.

In this single-center, retrospective study bilateral intravitreal injections, including bevacizumab, ranibizumab, and aflibercept, were performed in 630 eyes of 103 patients.

There was an average of 3.06 bilateral injections per patient, with most patients (66.7%) receiving aflibercept. The most common indication for treatment was center-involving diabetic macular edema in 64.9%.

In this study, 79% of injected eyes had drug taken from the same vial.

There was 1 case of endophthalmitis and systemic complications including 2 cases of cerebral vascular accidents and 1 death.

Chia K, et al. Bilateral Same-Day Intravitreal Injections in a Tertiary Hospital. Presented at: ASRS 2022.